Progressive fibrosis is common in patients with Sjögren’s syndrome and Interstitial lung disease

Diou, Caroline; Debray, Marie‐Pierre; Bancal, Catherine; Sacré, Karim; Taillé, Camille; Khamis, Warda; Dhôte, Robin; Borie, R.; Nunès, Hilario; Uzunhan, Y.; Crestani, Bruno

doi:10.1183/13993003.congress-2021.pa2245

Search citation statements

Order By: Relevance

Paper Sections

Select...

Ilds/dplds Of Known Origin1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article1

Relationship

Self Cite1

Independent0

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite immunosuppressive therapy, 43% of the patients were reported to have an FVC decline ≥10% at follow-up, with survival rates of 80% at 5 years and 62% at 10 years. However, given the nature of this clinical cohort, it is possible there was a selection bias of patients with a progressive disease course [ 27 ].…”

Section: Ilds/dplds Of Known Originmentioning

confidence: 99%

ERS International Congress 2021: highlights from the Interstitial Lung Diseases Assembly

et al. 2022

Self Cite

View full text Add to dashboard Cite

This article provides an overview of scientific highlights in the field of interstitial lung disease (ILD), presented at the virtual European Respiratory Society Congress 2021. A broad range of topics was discussed this year, ranging from translational and genetic aspects to novel innovations with the potential to improve the patient pathway. Early Career Members summarize a selection of interesting findings from different congress sessions, together with the leadership of Assembly 12 – Interstitial Lung Disease.

show abstract

Section: Ilds/dplds Of Known Originmentioning

confidence: 99%